BMS‐986122
Chemical compound
From Wikipedia, the free encyclopedia
BMS‐986122 is a selective positive allosteric modulator (PAM) of the μ-opioid receptor (MOR).[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | BMS986122; BMS-122; BMS122 |
| Drug class | μ-Opioid receptor positive allosteric modulator (MOR PAM) |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H15BrClNO3S2 |
| Molar mass | 448.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MOR PAMs like BMS-986122 could be useful as novel analgesics with reduced side effects compared to conventional opioid analgesics.[4][5] However, the potential specifically of BMS-986121 and BMS-986122 as pharmaceutical drugs may be restricted due to their complex synthesis.[4][3]
Pharmacology
Pharmacodynamics
BMS-986122 can enhance the affinity and efficacy of various orthosteric MOR agonists, including the endogenous opioid peptides, for the MOR.[1][2] However, its effects are dependent on the ligand, and in the case of morphine, it enhances efficacy without affecting affinity.[1] BMS‐986122 has no MOR agonist activity, is selective for the MOR, and lacks PAM activity at the δ-opioid receptor (DOR).[1] However, it has been identified as a silent allosteric modulator (SAM) of the DOR and κ-opioid receptor (KOR).[6]
The drug has analgesic effects in animals.[2][4] In contrast to MOR agonists, BMS-986122 does not appear to promote opioid-induced constipation, respiratory depression, or reward.[4][7] The drug has been found to attenuate opioid tolerance in rodents, specifically in terms of analgesia.[8] Besides its analgesic effects, BMS-986122 has been found to enhance the analgesic effects of non-opioid analgesics such as clonidine and gabapentin in rodents.[9]
History
BMS-986122 was first described in 2013, and along with BMS-986121, was the first selective MOR PAM to be discovered.[1][10] They were identified via high-throughput screening (HTS).[1][10] Their characterization led to the discovery of a putative conserved allosteric site across the MOR and other opioid receptors.[6]
Related compounds
A dual DOR and κ-opioid receptor (KOR) PAM, BMS-986187, derived from BMS-986122, has been developed and is selective for these receptors over the MOR.[11][1][2][6][12]
Another MOR PAM with a simpler synthesis, MS1, was subsequently developed and has shown similar effects to those of BMS-986122.[4][2] Additionally, ignavine, a natural MOR PAM found in Aconitum, has also been identified.[1][2][13]
In 2024, ketamine and its metabolites norketamine and hydroxynorketamine (HNK) were identified as highly potent MOR, DOR, and KOR PAMs (active at a concentration of as low as 1 nM).[14] These actions were implicated in their potential antidepressant and analgesic effects.[14]